U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H27ClN2O2.2ClH
Molecular Weight 471.848
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of PINOXEPIN HYDROCHLORIDE

SMILES

Cl.Cl.OCCN1CCN(CC\C=C2\C3=C(COC4=C2C=C(Cl)C=C4)C=CC=C3)CC1

InChI

InChIKey=URBVIISFALGUAB-LZWUXPCZSA-N
InChI=1S/C23H27ClN2O2.2ClH/c24-19-7-8-23-22(16-19)21(20-5-2-1-4-18(20)17-28-23)6-3-9-25-10-12-26(13-11-25)14-15-27;;/h1-2,4-8,16,27H,3,9-15,17H2;2*1H/b21-6-;;

HIDE SMILES / InChI

Molecular Formula C23H27ClN2O2
Molecular Weight 398.926
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Pinoxepin belongs to the dibenzoxepine series of drugs which are characterized by a 6-7-6 tricyclic nuclear structure. Clinical studies indicated that pinoxepin was a potent antipsychotic-sedative equally effective to chlorpromazine and thioridazine. Pinoxepin in studies with chronic schizophrenic patients displayed useful effects on behavior without unduly prominent side effects. In doses above 300 mg seizures are reported and more frequent changes in liver-function tests were noted than with standard drug, but below 300 mg pinoxepin was found to have side effects similar to chlorpromazine and marked sedative effects.

Approval Year

PubMed

PubMed

TitleDatePubMed
P-5227: an active dibenzoxepine antipsychotic.
1966 May
A PRELIMINARY STUDY OF P-5227, a new active tricyclic antipsychotic agent.
1966 Oct
Pinoxepin vs. chlorpromazine: a double-blind comparison.
1967 Aug
Effects of pinoxepin and imipramine on the mesencephalic reticular formation and amygdaloid complex in the cat: neurophysiological and clinical correlations in human subjects.
1967 Jul
Comparison of P-5227 and thioridazine in chronic schizophrenic patients.
1967 Sep-Oct
Comparison of perphenazine and P-5227 in chronic schizophrenics: clinical and EEG effects.
1969 May-Jun

Sample Use Guides

Daily dosage: 50 mg - 1st week, 100mg - 2nd week, 150 mg - 3rd week, 200 mg - 4th week, 250 mg - 5th week, 250-400 mg - 6-10th weeks.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:23:11 GMT 2023
Edited
by admin
on Fri Dec 15 15:23:11 GMT 2023
Record UNII
7KE5R66TSY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PINOXEPIN HYDROCHLORIDE
USAN  
USAN  
Official Name English
P-5227
Code English
PINOXEPIN HCL
Common Name English
1-PIPERAZINEETHANOL, 4-(3-(2-CHLORODIBENZ(B,E)OXEPIN-11(6H)-YLIDENE)PROPYL)-, DIHYDROCHLORIDE, (Z)-
Common Name English
PINOXEPIN HYDROCHLORIDE [USAN]
Common Name English
(Z)-4-[3-(2-Chlorodibenz[b,e]oxepin-11-(6H)-ylidene)propyl]-1-piperazineethanol dihydrochloride
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66883
Created by admin on Fri Dec 15 15:23:11 GMT 2023 , Edited by admin on Fri Dec 15 15:23:11 GMT 2023
Code System Code Type Description
ChEMBL
CHEMBL2110968
Created by admin on Fri Dec 15 15:23:11 GMT 2023 , Edited by admin on Fri Dec 15 15:23:11 GMT 2023
PRIMARY
NCI_THESAURUS
C76653
Created by admin on Fri Dec 15 15:23:11 GMT 2023 , Edited by admin on Fri Dec 15 15:23:11 GMT 2023
PRIMARY
PUBCHEM
6433591
Created by admin on Fri Dec 15 15:23:11 GMT 2023 , Edited by admin on Fri Dec 15 15:23:11 GMT 2023
PRIMARY
CAS
14008-46-9
Created by admin on Fri Dec 15 15:23:11 GMT 2023 , Edited by admin on Fri Dec 15 15:23:11 GMT 2023
PRIMARY
EPA CompTox
DTXSID301337302
Created by admin on Fri Dec 15 15:23:11 GMT 2023 , Edited by admin on Fri Dec 15 15:23:11 GMT 2023
PRIMARY
FDA UNII
7KE5R66TSY
Created by admin on Fri Dec 15 15:23:11 GMT 2023 , Edited by admin on Fri Dec 15 15:23:11 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY